Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Orgenesis Inc (ORGS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,822
  • Shares Outstanding, K 15,621
  • Annual Sales, $ 18,660 K
  • Annual Income, $ -18,290 K
  • 60-Month Beta 0.79
  • Price/Sales 4.19
  • Price/Cash Flow N/A
  • Price/Book 2.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/19
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.31
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +55.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.88 +14.55%
on 03/20/19
5.93 -5.70%
on 03/25/19
+0.50 (+9.82%)
since 02/26/19
3-Month
4.06 +37.68%
on 01/28/19
5.93 -5.70%
on 03/25/19
+1.20 (+27.33%)
since 12/26/18
52-Week
3.87 +44.44%
on 12/24/18
11.80 -52.63%
on 03/27/18
-5.42 (-49.23%)
since 03/26/18

Most Recent Stories

More News
Orgenesis Subsidiary Masthercell Global Announces Plans to Establish New Facility for Cell and Gene Therapy Commercial Manufacturing

Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced plans to establish a new, state-of-the-art production site for its Masthercell...

ORGS : 5.59 (+2.95%)
Orgenesis CEO to Participate in Panel at the 2019 BIO CEO & Investor Conference

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, will participate in a panel, "New Treatments...

ORGS : 5.59 (+2.95%)
Orgenesis' CSO Sara Ferber to Present to the International Research Training Group Hosted by Technische Universitat Dresden and the King's College London

GERMANTOWN, Md., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced that Orgenesis' Chief Scientific...

ORGS : 5.59 (+2.95%)
Orgenesis Announces the Opening of New Offices and Laboratories at Accessia Pharma in Liege, Belgium to Support its Point of Care Cellular Therapy Platform

Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider, today announced the opening of new offices and laboratories at Accessia Pharma in Liege, Belgium...

ORGS : 5.59 (+2.95%)
Orgenesis Announces U.S. Expansion of Masthercell Global Subsidiary

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that its subsidiary, Masthercell Global Inc. ("Masthercell Global"), is expanding...

ORGS : 5.59 (+2.95%)
Orgenesis Subsidiary Atvio Biotech to Present at Phacilitate Leaders World 2019 Conference

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, from Atvio Biotech Ltd. management, which is...

ORGS : 5.59 (+2.95%)
Orgenesis CEO Selected to Participate in Cell and Gene Therapy Workshop at Biotech Showcase 2019 in California

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced that Vered Caplan, Chief Executive Officer, has been selected to participate in...

ORGS : 5.59 (+2.95%)
Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PPL Corporation (NYSE:PPL),...

CUI : 1.23 (unch)
TCON : 1.35 (-4.26%)
ORGS : 5.59 (+2.95%)
INSG : 4.81 (+0.21%)
SGMS : 20.99 (+0.43%)
PPL : 32.45 (+0.31%)
Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform

Orgenesis Inc. (NASDAQ: ORGS), a developer, manufacturer and service provider of advanced cell therapies, today announced a collaboration with MangoGen Pharma Inc. (MangoGen), initially focused on the...

ORGS : 5.59 (+2.95%)
Orgenesis CEO Vered Caplan to Present at William Blair's Biotech Focus Day Series: Cell and Gene Therapy Manufacturing

Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell therapies, manufacturer and service provider today announced that Vered Caplan, CEO of Orgenesis, will participate in William Blair's Biotech...

ORGS : 5.59 (+2.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More Share

Trade ORGS with:

Business Summary

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing...

See More

Key Turning Points

2nd Resistance Point 5.79
1st Resistance Point 5.69
Last Price 5.59
1st Support Level 5.39
2nd Support Level 5.20

See More

52-Week High 11.80
Fibonacci 61.8% 8.77
Fibonacci 50% 7.84
Fibonacci 38.2% 6.90
Last Price 5.59
52-Week Low 3.87

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar